sensei(SNSE) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - SNS-101 Phase 1/2 dose expansion clinical data expected in the first half of 2025 - - Organizational restructuring to focus resources on advancing the clinical development of SNS-101 - - Cash runway extended into the second quarter of 2026 - BOSTON, MA – November 14, 2024 – Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and developmen ...